Separately, a Delaware jury in late October found that Masimo’s current products did not infringe any of Apple’s patents. The ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

but current Masimo products were not found to infringe. Subscribe to the Benzinga Tech Trends newsletter to get all the latest tech developments delivered to your inbox. Apple’s legal team ...

markets sells and licenses premium and luxury audio sound products and related integration technologies. Understanding the Numbers: Masimo's Finances Market Capitalization Analysis: The company's ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

“Apple primarily sought an injunction against Masimo’s current products, and the jury’s verdict is a victory for Masimo on that issue,” Masimo said. Apple said in a statement that it was ...

Young said Masimo is lowering corporate overhead costs, with cuts such as selling the corporate jet and reducing marketing expenses for products that aren't producing meaningful revenue and returns.

Masimo MASI is set to give its latest quarterly ... remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures ...